124 related articles for article (PubMed ID: 27329154)
21. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Ruan M; Liu M; Dong Q; Chen L
J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
[TBL] [Abstract][Full Text] [Related]
22. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription.
Wang Y; Yun Y; Wu B; Wen L; Wen M; Yang H; Zhao L; Liu W; Huang S; Wen N; Li Y
Oncotarget; 2016 Jul; 7(30):47985-47997. PubMed ID: 27351131
[TBL] [Abstract][Full Text] [Related]
23. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.
Wei WJ; Shen CT; Song HJ; Qiu ZL; Luo QY
Oncol Rep; 2016 Sep; 36(3):1576-84. PubMed ID: 27432558
[TBL] [Abstract][Full Text] [Related]
24. Expression of hypoxia-related glucose transporters GLUT1 and GLUT3 in benign, malignant and non-neoplastic thyroid lesions.
Jóźwiak P; Krześlak A; Pomorski L; Lipińska A
Mol Med Rep; 2012 Sep; 6(3):601-6. PubMed ID: 22752218
[TBL] [Abstract][Full Text] [Related]
25. Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras.
Prante O; Maschauer S; Fremont V; Reinfelder J; Stoehr R; Szkudlinski M; Weintraub B; Hartmann A; Kuwert T
J Nucl Med; 2009 Aug; 50(8):1364-70. PubMed ID: 19652218
[TBL] [Abstract][Full Text] [Related]
26. PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells.
Morani F; Phadngam S; Follo C; Titone R; Aimaretti G; Galetto A; Alabiso O; Isidoro C
J Mol Endocrinol; 2014 Oct; 53(2):247-58. PubMed ID: 25125078
[TBL] [Abstract][Full Text] [Related]
27. mTOR Pathway in Papillary Thyroid Carcinoma: Different Contributions of mTORC1 and mTORC2 Complexes for Tumor Behavior and
Tavares C; Eloy C; Melo M; Gaspar da Rocha A; Pestana A; Batista R; Bueno Ferreira L; Rios E; Sobrinho Simões M; Soares P
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29757257
[TBL] [Abstract][Full Text] [Related]
28. Combined RNA interference of hexokinase II and (131)I-sodium iodide symporter gene therapy for anaplastic thyroid carcinoma.
Kim JE; Ahn BC; Hwang MH; Jeon YH; Jeong SY; Lee SW; Lee J
J Nucl Med; 2011 Nov; 52(11):1756-63. PubMed ID: 21994409
[TBL] [Abstract][Full Text] [Related]
29. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
30. LARP7 in papillary thyroid carcinoma induces NIS expression through suppression of the SHH signaling pathway.
Sui X; Sui Y; Wang Y
Mol Med Rep; 2018 Jun; 17(6):7521-7528. PubMed ID: 29620212
[TBL] [Abstract][Full Text] [Related]
31. Papillary carcinoma of the thyroid: high expression of COX-2 and low expression of KAI-1/CD82 are associated with increased tumor invasiveness.
Scarpino S; Duranti E; Giglio S; Di Napoli A; Galafate D; Del Bufalo D; Desideri M; Socciarelli F; Stoppacciaro A; Ruco L
Thyroid; 2013 Sep; 23(9):1127-37. PubMed ID: 23617728
[TBL] [Abstract][Full Text] [Related]
32. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma.
Faustino A; Couto JP; Pópulo H; Rocha AS; Pardal F; Cameselle-Teijeiro JM; Lopes JM; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1139-49. PubMed ID: 22549934
[TBL] [Abstract][Full Text] [Related]
33. Tumor suppressor role of the CL2/DRO1/CCDC80 gene in thyroid carcinogenesis.
Ferraro A; Schepis F; Leone V; Federico A; Borbone E; Pallante P; Berlingieri MT; Chiappetta G; Monaco M; Palmieri D; Chiariotti L; Santoro M; Fusco A
J Clin Endocrinol Metab; 2013 Jul; 98(7):2834-43. PubMed ID: 23666966
[TBL] [Abstract][Full Text] [Related]
34. [The effect of TFF3 on the proliferation and migration of papillary thyroid carcinoma K1 cell].
Zheng X; Zhang T; Wu J; Zhang W; Zhang J; Wang B
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Jul; 29(13):1194-8. PubMed ID: 26540923
[TBL] [Abstract][Full Text] [Related]
35. Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer.
Kim H; Na KJ; Choi JH; Ahn BC; Ahn D; Sohn JH
Eur Arch Otorhinolaryngol; 2016 Jun; 273(6):1569-76. PubMed ID: 25971994
[TBL] [Abstract][Full Text] [Related]
36. Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake.
Mian C; Barollo S; Pennelli G; Pavan N; Rugge M; Pelizzo MR; Mazzarotto R; Casara D; Nacamulli D; Mantero F; Opocher G; Busnardo B; Girelli ME
Clin Endocrinol (Oxf); 2008 Jan; 68(1):108-16. PubMed ID: 17854396
[TBL] [Abstract][Full Text] [Related]
37. miR-146a and miR-146b in the diagnosis and prognosis of papillary thyroid carcinoma.
Qiu Z; Li H; Wang J; Sun C
Oncol Rep; 2017 Nov; 38(5):2735-2740. PubMed ID: 29048684
[TBL] [Abstract][Full Text] [Related]
38. Afamin--A pleiotropic glycoprotein involved in various disease states.
Dieplinger H; Dieplinger B
Clin Chim Acta; 2015 Jun; 446():105-10. PubMed ID: 25892677
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological characteristics including BRAF V600E mutation status and PET/CT findings in papillary thyroid carcinoma.
Choi EK; Chong A; Ha JM; Jung CK; O JH; Kim SH
Clin Endocrinol (Oxf); 2017 Jul; 87(1):73-79. PubMed ID: 28329426
[TBL] [Abstract][Full Text] [Related]
40. Biological significance of 18F-FDG uptake on PET in patients with non-small-cell lung cancer.
Kaira K; Serizawa M; Koh Y; Takahashi T; Yamaguchi A; Hanaoka H; Oriuchi N; Endo M; Ohde Y; Nakajima T; Yamamoto N
Lung Cancer; 2014 Feb; 83(2):197-204. PubMed ID: 24365102
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
